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OBJECTIVES The purpose of this study was to assess the effect of oral azimilide dihydrochloride (AZ) 100
mg versus placebo on the onset, termination, and prevalence of atrial fibrillation (AF) in a
subpopulation of patients in the Azimilide Postinfarct Survival Evaluation (ALIVE) trial.
BACKGROUND Previous clinical trials have demonstrated the antiarrhythmic effects of AZ in patients with
AF. Azimilide was investigated for its effects on mortality in patients with depressed left
ventricular (LV) function after recent myocardial infarction (MI) and in a subpopulation of
patients with AF.
METHODS A total of 3,381 post-MI patients with depressed LV function were enrolled in this
randomized, placebo-controlled, double-blind study of AZ 100 mg on all-cause mortality. A
total of 93 patients had AF on the baseline 12-lead electrocardiogram (ECG). An additional
27 patients developed AF after initially being in sinus rhythm at randomization. These
patients were identified through 12-lead ECGs obtained during routine visits at week 2,
months 1, 4, 8, and 12.
RESULTS Patients with AF at baseline had a higher mortality than those without AF (p  0.0006).
Among AF patients, there was no difference in mortality between AZ patients and placebo
patients (p 0.82). Fewer AZ patients developed AF than placebo patients (p 0.04). More
AZ patients than placebo patients converted to sinus rhythm, but this difference did not
achieve statistical significance (p  0.076). Over one-year follow-up, more AZ patients were
in sinus rhythm than placebo patients (p  0.04).
CONCLUSIONS Azimilide was safe and effective AF therapy in patients with depressed LV function after an
MI. (J Am Coll Cardiol 2004;43:1211–6) © 2004 by the American College of Cardiology
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the clinical consequence of atrial fibrillation (AF) is am-
lified in patients with left ventricular (LV) dysfunction and
linical congestive heart failure (1). In patients with a low
V ejection fraction (LVEF), AF is associated with a higher
ncidence of congestive heart failure and decreased survival,
n both males and females (2). Such high-risk patients are
requently more resistant to pharmacologic or electrical
ardioversion and more prone to AF recurrence (3). The use
f many antiarrhythmic drugs is not indicated in such
atients either because of the lack of efficacy data or concern
From *The Methodist DeBakey Heart Center and Department of Medicine,
ection of Cardiology, Baylor College of Medicine, Houston, Texas; †Department of
ardiology, Veterans Affairs Medical Center, Washington, DC; ‡Procter & Gamble
harmaceuticals, Cincinnati, Ohio; §Department of Cardiology, Policlinico S.
atteo, IRRCS and University of Pavia, Italy; and Department of Cardiology, St.
eorge’s Hospital, London, United Kingdom. Supported by a grant from the Health
are Research Center, Procter & Gamble Pharmaceuticals, Inc., Cincinnati, Ohio.
rs. Pratt and Camm are consultants for the scientific and regulatory development of
zimilide and served as co-chair and chair, respectively, on the ALIVE Steering
ommittee. Dr. Singh was a member of the ALIVE Executive Medical Committee,
nd Dr. Schwartz was a member of the ALIVE Steering Committee. Presented as an
bstract at the 75th Annual American Heart Association’s Scientific Sessions,
ovember 2002.
Manuscript received June 23, 2003; revised manuscript received October 1, 2003,(ccepted October 20, 2003.egarding proarrhythmic risk and/or negative inotropic ef-
ects (4).
Azimilide dihydrochloride (AZ) is a Vaughan-Williams
lass III antiarrhythmic drug, which is being developed
rimarily for AF (5) and also as adjunctive antiarrhythmic
herapy in patients with implantable cardioverter defibrilla-
ors (6). Azimilide has a unique electrophysiologic profile
ossessing both IKr and IKs channel blocking properties. In
revious trials, AZ at doses of 100 mg and 125 mg daily
rolonged the time to first symptomatic recurrence of AF
nd atrial flutter (5,7).
In general, the clinical experience with antiarrhythmic
rugs in patients with AF associated with moderate-to-
evere heart failure is limited (8). One approach to increase
he knowledge of specific antiarrhythmic drugs in these
igh-risk patients is to conduct subpopulation analyses of
afety and efficacy in AF patients participating in large,
andomized, placebo-controlled mortality trials. The goal of
his paper is to expand this knowledge to include AZ, by
nalysis of a recently completed mortality trial.
The Azimilide Postinfarct Survival Evaluation (ALIVE)
rial (9) was a placebo-controlled, randomized, prospective
rial of patients with a recent acute myocardial infarction
MI) and in whom LV systolic dysfunction was present.
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Azimilide in Patients With AF April 7, 2004:1211–6he primary end point was total mortality focused on
igh-risk patients. The results showed a neutral association
f AZ to mortality (primary efficacy analysis: p  0.74;
azard ratio [HR]  0.95; 95% confidence interval [CI] 
.71 to 1.27). An important prespecified objective of the
LIVE trial was to assess the effect of AZ 100 mg versus
lacebo on the onset, termination, and prevalence of AF.
ETHODS
his report concerns an analysis of a subgroup of patients in
he ALIVE trial who had AF at randomization or devel-
ped AF during the one-year follow-up. A total of 3,717
atients were enrolled in the ALIVE trial. Briefly, the
nclusion criteria for ALIVE required a measured LVEF of
5% to 35% in patients five to 21 days after acute MI. The
andomized groups included: placebo (n  1,690); AZ 100
g (n  1,691); and an additional lower AZ dose group of
5 mg (n 336), which was discontinued due to enrollment
ifficulties. These latter patients are not considered further
n the analyses presented, which focused on the remaining
,381 patients followed for one year.
At randomization, a total of 93 patients had AF on the
aseline 12-lead electrocardiogram (ECG). They are the
rimary focus of this analysis. An additional 27 patients
eveloped AF after initially being in sinus rhythm at
andomization. These patients were identified through 12-
ead ECGs that were obtained during routine visits at week
as well as months 1, 4, 8, and 12. The AF case report form
as not designed to capture symptoms.
utcome measures. There were several prespecified anal-
ses conducted for patients with documented AF captured
y 12-lead ECG at randomization as well as those who were
ree of AF at baseline, but developed the arrhythmia during
he trial, which were assessed through routine 12-lead
CGs. The primary prespecified end points were: 1) for
hose not in AF at baseline, time-to-first documented AF
vent during any visit (n  27); 2) for those in AF at
aseline (n  93), time-to-first spontaneous conversion to
inus rhythm captured by the 12-lead ECG during any visit;
nd 3) the percent of patients with AF at baseline who were
Abbreviations and Acronyms
AF  atrial fibrillation
ALIVE  Azimilide Postinfarct Survival Evaluation
AZ  azimilide dihydrochloride
CHF-STAT  Survival Trial of Antiarrhythmic Therapy
in Congestive Heart Failure
CI  confidence interval
DIAMOND  Danish Investigators of Arrhythmia and
Mortality on Dofetilide trial
HR  hazard ratio
LV  left ventricle/left ventricular
LVEF  left ventricular ejection fraction
MI  myocardial infarction
NYHA  New York Heart Associationn sinus rhythm at each subsequent visit. The latter analysis considers the prevalence of AF over time in each random-
zed study group at defined intervals throughout the one-
ear trial.
tatistical methods. Analyses are reported according to
he intention-to-treat principle. For time-to-first event
nalysis, Kaplan-Meier estimates were used with a log-rank
est to compare the probability of freedom from recurrent
F, and the Cox proportional hazards model to calculate
azard ratios and 95% CI (10). Repeated measure analysis
tilizing generalized estimating equations (11) was used for
he prevalence of AF among treatment groups during the
ne-year follow-up.
In addition, the Cox proportional hazards regression
nalysis of total mortality was used among all patients in AF
at randomization vs. those patients not in AF) to explore
he effect of AF on all-cause mortality, after adjustment was
ade for age, sex, beta-blocker, and angiotensin-converting
nzyme inhibitor usage, LVEF, congestive heart failure,
iabetes, hypertension, and New York Heart Association
NYHA) class.
ESULTS
f the total of 3,381 patients randomized in the ALIVE
rial, 120 had AF during the trial, 93 patients at random-
zation, and an additional 27 patients developed AF during
he trial.
The baseline demographic characteristics of the ALIVE
atients in sinus rhythm at randomization, compared with
hose patients with AF, are presented in Table 1. Atrial
brillation patients were older (mean age, 68 vs. 60 years);
ore likely to have symptomatic (NYHA class II/III)
able 1. Demographic Comparison of ALIVE Patients With or
ithout Atrial Fibrillation at Randomization
Atrial
Fibrillation
(n  93)
Sinus
Rhythm
(n  3,278*) p Value
ge (mean, yrs) 68 60  0.001
emale/male (%) 28%/72% 22%/78% NS
VEF (mean, %) 28.5% 29.4% NS
15%–25% 26% 23% NS
26%–35% 74% 77% NS
YHA class
I 28% 48% NS
II/III 72% 52%  0.0001
rior MI 35% 30% NS
ypertension 69% 55%  0.01
iabetes 25% 25% NS
edication at
randomization
Beta-blocker 60% 74% 0.01
ACE inhibitor 88% 87% NS
Aspirin 73% 89% 0.001
10 patients did not have baseline ECG.
ACE  angiotension-converting enzyme inhibitors; ALIVE  Azimilide Postin-
arct Survival Evaluation trial; LVEF  left ventricular ejection fraction; MI 
yocardial infarction; NS  not statistically significant; NYHA  New York Heart
ssociation.ongestive heart failure (72% vs. 52%); had a higher fre-
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April 7, 2004:1211–6 Azimilide in Patients With AFuency of hypertension (69% vs. 55%); and less beta-blocker
60% vs. 74%) and aspirin use (73% vs. 89%) (Table 1).
The influence of AF on total mortality is presented by
aplan-Meier estimate in Figure 1A. Cox proportional
azards model was used to estimate the hazard ratio and the
5% CIs before and after statistical adjustment for relevant
ovariates (age, gender, hypertension, heart failure, LVEF,
iabetes, NYHA class, beta-blocker, and angiotensin-
onverting enzyme use) in Figure 1B. In both analyses, the
atients with AF had a higher mortality (unadjusted:
og-rank p  0.0006, HR  2.1, 95% CI  1.4 to 3.3;
djusted: p  0.075, HR  1.5, 95% CI  0.96 to 2.34).
lthough, the adjusted analysis achieved borderline statis-
ical significance, the AF patients after adjustment had a
0% higher chance of death than patients not in AF at
aseline.
Among AF patients, there was no difference in mortality
etween placebo and AZ patients (p  0.82; HR  1.1;
5% CI  0.5 to 2.7). This was consistent with the overall
eutral mortality results of the ALIVE trial (p  0.74; HR
0.95; 95% CI  0.71 to 1.27) (Fig. 2).
Several prespecified analyses were used to investigate the
ffect of 100 mg AZ compared with placebo on AF. A
emographic comparison of the randomized patients with
F is presented in Table 2. The two treatment groups were
enerally well balanced. However, the AZ group was
haracterized by a higher percentage of diabetes and hyper-
ension. Despite these trends, none of these characteristics
chieved statistical significance.
Figure 3 depicts the time-to-new documented onset of
F among patients not in AF at baseline. Fewer AZ
igure 1. (A) All-cause mortality among atrial fibrillation (AF) patients
djusted for age, gender, hypertension, beta-blocker, angiotensin-converti
eart Association class. SR  sinus rhythm.
igure 2. All-cause mortality among patients in atrial fibrillation at
iaseline. AZ  azimilide dihydrochloride.atients developed AF than placebo patients (8 of 1,630
0.5%] vs. 19 of 1,648 [1.2%], respectively; p 0.04; HR
.43; 95% CI  0.19 to 0.99).
Further analysis considers the time-to-first spontaneous
onversion to sinus rhythm, which occurred in 15 of 56
26.8%) of AZ patients compared with 4 of 37 (10.8%)
lacebo patients (p 0.076, HR 2.63, 95% CI 0.87 to
.93) (Fig. 4).
An additional analysis included the prevalence of the
rrhythmia at designated time intervals during the trial after
andomization among those patients in AF at baseline. This
nalysis is depicted in Figure 5. Over one-year follow-up of
atients in AF at baseline, a repeated-measure analysis of
he AF prevalence showed more AZ patients compared
ith placebo patients were in sinus rhythm (p  0.04).
Serious adverse events were similar in AZ and placebo
atients (Table 3). The pattern of adverse events did not
iffer from the ALIVE trial as a whole. However, among
atients not in AF at baseline, there were fewer AZ patients
ith new or worsening heart failure than placebo patients
97 of 1,630 [6%] vs. 127 of 1,648 [8%], respectively; p 
.05). In the total ALIVE population, 5 of 1,691 (0.3%) AZ
atients and 1 of 1,690 (0.06%) placebo patients developed
orsade de pointes based on event committee assessment.
able 2. ALIVE Patients With Atrial Fibrillation at
andomization: Demographics
Placebo
(n  37)
Azimilide (100 mg)
(n  56)
ge (mean, yrs) 69 68
emale/male (%) 30/70 27/73
VEF (mean, %) 28.9% 28.3%
YHA class
I 30% 27%
II/III 70% 73%
rior MI 27% 27%
ypertension 65% 71%
iabetes 19% 29%
edication at randomization
Beta-blocker 65% 57%
ACE inhibitor 89% 88%
Aspirin 73% 73%
CE  angiotensin-converting enzyme; ALIVE  Azimilide Postinfarct Survival
valuation trial; LVEF  left ventricular ejection fraction; MI  myocardial
patients not in AF at baseline. (B) Effect of AF on all-cause mortality
zyme inhibitors, ejection fraction, heart failure, diabetes, and New Yorkversus
ng ennfarction; NYHA  New York Heart Association.
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Azimilide in Patients With AF April 7, 2004:1211–6evere neutropenia (absolute neutrophil count 500 cells/
l) occurred in 15 of 1,691 (0.9%) AZ patients and 4 of
,690 (0.2%) placebo patients. Azimilide-associated neutro-
enia had a predictable onset time (19 to 48 days) and
eversed after drug withdrawal. No patients developed
ife-threatening infections. There was only one torsade de
ointes case (AZ patient) and no severe neutropenia cases
mong AF substudy.
ISCUSSION
he ALIVE trial was a multinational, randomized, double-
lind, prospective trial of AZ versus placebo in surviving MI
atients with moderate-to-severe LV systolic dysfunction,
ver half of whom had NYHA II/III congestive heart
ailure. As such, it included patients with concomitant AF
t randomization as well as patients who developed AF
uring the one-year trial.
The major conclusions based on the analysis of these
igh-risk patients with AF at baseline or those who devel-
ped AF during the trial are: 1) fewer AZ patients devel-
ped AF than placebo patients (p  0.04); 2) more AZ
atients converted from AF to sinus rhythm than placebo
atients, but this difference did not achieve statistical
ignificance (p  0.076); and 3) over one-year follow-up of
atients in AF at baseline, a repeated-measure analysis of
he AF prevalence showed more AZ patients were in sinus
hythm compared with placebo patients (p  0.04). These
bservations are consistent with data from previous AZ
andomized studies in AF population (5).
In the ALIVE trial, the analysis of AF was considered an
mportant and prespecified primary subpopulation analysis.
igure 4. Time-to-first spontaneous conversion to sinus rhythm (SR)
mong patients in atrial fibrillation at baseline. AZ  azimilide dihydro-
igure 3. Time-to-first documented atrial fibrillation among patients not
n atrial fibrillation at baseline. AZ  azimilide dihydrochloride.hloride.hese results can be compared with those of dofetilide and
miodarone and their respective mortality trials, the Danish
nvestigators of Arrhythmia and Mortality on Dofetilide
rial (DIAMOND) (dofetilide) (12–14) and the Survival
rial of Antiarrhythmic Therapy in Congestive Heart
ailure (CHF-STAT) (amiodarone) (15,16). These analy-
es were pivotal as the basis for recommending only these
wo drugs as initial therapy for AF in patients with LV
ystolic dysfunction and clinical congestive heart failure in
he current AF management guidelines (17). All these
ubstudies are comprised of AF patients with cardiomyop-
thy and clinical congestive heart failure. The placebo-
ubtracted efficacy rates in these three trials were remarkably
imilar for maintenance of sinus rhythm: AZ, 28%; dofeti-
ide, 25%; amiodarone, 23%. Direct comparisons are imper-
ect with some differences in the severity of heart failure and
ean follow-up, but the extent of LV dysfunction is similar.
The increased risk of AF and mortality in congestive
eart failure patients is well established (2,18). In the
ramingham experience, heart failure increased the risk of
eveloping AF 4.5-fold in men and 5.9-fold in women,
fter multivariate adjustments (1). Additionally, in the
IAMOND trials, AF was 3 times more prevalent
25.8% vs. 7.6%) in the DIAMOND congestive heart
ailure population than in the DIAMOND MI population.
trial fibrillation was also associated with an increased risk
f death, by approximately 25% in DIAMOND congestive
eart failure patients, compared with patients in sinus
hythm (12–14).
The potential reasons for this increased mortality with
F include hemodynamic compromise due to lack of atrial
ontraction, the potential effect of tachyarrhythmic cardio-
yopathy, and embolic consequences. The mortality results
f ALIVE are consistent with these estimates, with the AF
opulation having a higher risk of death, even after statis-
ical adjustment for relevant covariates affecting mortality.
mportantly, mortality in AF patients on AZ was compa-
able with placebo.
The ALIVE population is similar to DIAMOND
dofetilide) and CHF-STAT (amiodarone), with a mean
VEF of 29%, more than half of whom had NYHA II/III
linical congestive heart failure and a substantial (15% at one
ear) placebo mortality.
igure 5. Prevalence of atrial fibrillation (Afib) at each visit: a follow-up of
atients in Afib at baseline. Gray bars  placebo; black bars  100 mg
zimilide.To clarify the risk/benefit analysis, one should consider
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April 7, 2004:1211–6 Azimilide in Patients With AFhe incidence of torsade de pointes ventricular tachyarrhyth-
ia reported on these three drugs were: dofetilide, 32 of
,511 (2.12%); amiodarone, 0 of 336 (0%); and AZ, 5 of
,691 (0.3%). An additional risk of severe neutropenia
ccurred more frequently in AZ (0.9%) compared with
lacebo patients (0.2%) in ALIVE. However, no patients
eveloped life-threatening infections.
In conclusion, this analysis demonstrated that the efficacy
f 100 mg AZ in AF patients in the ALIVE trial is
onsistent with the results of a meta-analysis of AZ in the
anagement of symptomatic, recurrent AF from four clin-
cal trials with 1,380 patients (7) showing that AZ doses of
00 and 125 mg/day significantly prolonged the time to
rrhythmia recurrence. Furthermore, in the AF trials of AZ,
hose patients with a history of ischemic heart disease or
eart failure had a greater treatment effect from AZ than
atients without a history of those conditions (5).
Additionally, the mortality in AF patients on AZ and
lacebo was comparable and consistent with results of the
LIVE trial (5). Furthermore, AZ patients in the ALIVE
rial were less likely than placebo patients to develop new or
orsening congestive heart failure. This finding is consis-
ent with the results of a study in patients with implantable
ardioverter defibrillators (mean LVEF  30.6%) showing
o effect of AZ on LVEF (6,9). The torsade de pointes and
evere neutropenia occurred more frequently in AZ patients
ompared with placebo patients (0.3% vs. 0.06% and 0.9%
s. 0.2%, respectively) as reported in previous studies.
orsade de pointes was associated with well-established risk
actors such as female gender, low potassium, and diuretic
herapy. Severe neutropenia had a predictable early onset
ime (19 to 48 days) and could be identified by weekly blood
onitoring during the first two to three months of dosing.
The results of ALIVE, together with the subpopulation
nalyses of AF patients, indicate that AZ is an effective and
afe therapy for AF in patients with depressed LV function
nd an MI.
cknowledgments
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